← Back to Screener
Cullinan Therapeutics, Inc. Common Stock (CGEM)
Price$13.51
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)10.90%
Price vs S&P 500 (4W)-7.14%
VGM Score52.28
Market Capitalization$830.30M
All Metrics
Book Value / Share (Quarterly)$5.96
P/TBV (Annual)0.70x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-2.91
Price vs S&P 500 (YTD)22.37%
EPS (TTM)$-3.72
10-Day Avg Trading Volume1.04M
EPS Excl Extra (TTM)$-3.72
EPS (Annual)$-3.11
ROI (Annual)-28.35%
Cash / Share (Quarterly)$5.73
ROA (Last FY)-26.92%
EBITD / Share (TTM)$-4.04
ROE (5Y Avg)-16.56%
Cash Flow / Share (Annual)$-2.92
P/B Ratio2.27x
P/B Ratio (Quarterly)2.35x
Net Income / Employee (Annual)$-1,535,600
ROA (TTM)-47.64%
EV / EBITDA (TTM)6.58x
EPS Incl Extra (Annual)$-3.11
Current Ratio (Annual)10.25x
Quick Ratio (Quarterly)10.01x
3-Month Avg Trading Volume0.86M
52-Week Price Return54.58%
EV / Free Cash Flow (Annual)-0.85x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$10.96
P/S Ratio (Annual)43.84x
Asset Turnover (Annual)0.04x
52-Week High$16.74
EPS Excl Extra (Annual)$-3.11
CapEx CAGR (5Y)37.42%
26-Week Price Return18.82%
Quick Ratio (Annual)10.01x
13-Week Price Return-13.40%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)10.28x
Enterprise Value$755.22M
Book Value / Share Growth (5Y)7.14%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-356.34%
Cash / Share (Annual)$6.27
3-Month Return Std Dev65.56%
Net Income / Employee (TTM)$-2,027,900
ROE (Last FY)-28.35%
EPS Basic Excl Extra (Annual)$-3.11
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-3.72
ROI (TTM)-51.45%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$11.68
Price vs S&P 500 (52W)30.21%
Year-to-Date Return30.53%
5-Day Price Return-16.66%
EPS Normalized (Annual)$-3.11
ROA (5Y Avg)-15.57%
Net Profit Margin (Annual)-346.20%
Month-to-Date Return-17.82%
Cash Flow / Share (TTM)$-3.70
EBITD / Share (Annual)$-3.66
Operating Margin (Annual)-358.76%
ROI (5Y Avg)-16.56%
EPS Basic Excl Extra (TTM)$-3.72
P/TBV (Quarterly)0.80x
P/B Ratio (Annual)1.50x
Book Value / Share (Annual)$6.78
Price vs S&P 500 (13W)-21.65%
Beta0.11x
Revenue / Share (TTM)$0.00
ROE (TTM)-51.45%
52-Week Low$5.68
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.75est. -0.85
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.42
4.42
4.42
4.42
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CGEMCullinan Therapeutics, Inc. Common Stock | — | — | C | $13.51 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
Cullinan Therapeutics is a clinical-stage biopharmaceutical company focused on immunology and oncology therapies. The company develops treatments that inhibit key disease drivers or harness the immune system to eliminate diseased cells in cancer and autoimmune indications. Its pipeline leverages differentiated expertise in translational medicine and immunology to address unmet needs across multiple therapeutic areas.